Rituximab Plus MMF: FVC Benefits Seen at 6 Months But Not 1 Year in ILD, IIP
Although rituximab plus MMF improved ppFVC at 6 months in patients with NSIP and CTD-ILD, this positive FVC change was not maintained at 12 months.
Although rituximab plus MMF improved ppFVC at 6 months in patients with NSIP and CTD-ILD, this positive FVC change was not maintained at 12 months.
Official Bluesky of the ATS Assembly on Respiratory Cell and Molecular Biology (RCMB)
Young adults, particularly those ages 18-25, are more likely to be covered as dependents than adults overall (72% vs. 32%). The Affordable Care Act (ACA)…
Although obesity-related asthma is associated with worse asthma outcomes, optimal treatment approaches for this complex phenotype are still largely unavailable. This state-of-the-art review article…
BOSTON — Pregnant women with very severe interstitial lung disease had fewer term deliveries and more preterm births and miscarriages vs. women with a lower…
Older men with COPD experienced improved lung function, functional fitness and quality of life after partaking in a tai chi plus yoga program for 12…
Rationale: Although recent evidence suggested that glucagon-like peptide 1 receptor agonists (GLP1RAs) might reduce the risk of asthma exacerbations, it remains unclear which subpopulations might…
“.” American Journal of Respiratory Cell and Molecular Biology, 71(5), pp.
This volume addresses rising distrust in food safety, shifts in social media content moderation, and the trend of self-diagnosis and treatment based on social media…
KFF’s Jen Kates and AVAC’s Suraj Madoori lay out the challenges and the priorities in 2025 and beyond. In the days, months and years ahead…
Indwelling pleural catheters (IPCs) have rapidly grown in popularity since their introduction for the management of recurrent pleural effusions. In malignant pleural effusions especially, there…